For research use only. Not for therapeutic Use.
Edaglitazone is a potent, selective and orally active PPARγ agonist, with EC50s of 35.6 nM and 1053 nM for PPARα and PPARγ, respectively. Edaglitazone displays antiplatelet, antidiabetic and anti-hyperglycemic activity[1][2][3].
Edaglitazone (3-16 μM; 5 min) inhibits the collagen (1.2 μg/mL)-induced platelet aggregation. Edaglitazone increases the intraplatelet levels of cAMP in a concentration dependent manner. Edaglitazone preventes the Collagen-induced intraplatelet levels of PPARγ decrease[3].
Edaglitazone (4.4 mg/kg; p.o. daily for 10 days) enhances insulin sensitivity in obese rats[2].
| Catalog Number | I006587 |
| CAS Number | 213411-83-7 |
| Synonyms | 5-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-1-benzothiophen-7-yl]methyl]-1,3-thiazolidine-2,4-dione |
| Molecular Formula | C24H20N2O4S2 |
| Purity | ≥95% |
| InChI | InChI=1S/C24H20N2O4S2/c1-14-18(25-23(30-14)15-5-3-2-4-6-15)9-11-29-19-8-7-16(21-17(19)10-12-31-21)13-20-22(27)26-24(28)32-20/h2-8,10,12,20H,9,11,13H2,1H3,(H,26,27,28) |
| InChIKey | HAAXAFNSRADSMK-UHFFFAOYSA-N |
| SMILES | CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=C4C=CSC4=C(C=C3)CC5C(=O)NC(=O)S5 |
| Reference | [1]. Dietz M, et, al. Comparative molecular profiling of the PPARα/γ activator aleglitazar: PPAR selectivity, activity and interaction with cofactors. ChemMedChem. 2012 Jun;7(6):1101-11. [2]. Fürnsinn C, et, al. Chronic and acute effects of thiazolidinediones BM13.1258 and BM15.2054 on rat skeletal muscle glucose metabolism. Br J Pharmacol. 1999 Nov;128(6):1141-8. [3]. Muñoz-Gutiérrez C, et, al. Study of the interactions between Edaglitazone and Ciglitazone with PPARγ and their antiplatelet profile. Life Sci. 2017 Oct 1;186:59-65. |
